Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease

Biscetti, Federico; Nardella, Elisabetta; Bonadia, Nicola; Angelini, Flavia; Pitocco, Dario; Santoliquido, Angelo; Filipponi, Marco; Landolfi, Raffaele; Flex, Andrea

doi:10.1186/s12933-019-0880-7

Cited by 54 publications

(47 citation statements)

References 36 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently low levels of Omentin-1, which is an adipokine with anti-in ammatory properties, were shown to be associated with the presence and severity of PAOD in T2D (36). However in ammatory markers like IL-6 and hsCRP were not associated with the progression of the calci cation in our study.…”

Section: Discussioncontrasting

confidence: 73%

Circulating Receptor Activator of Nuclear factor kB Ligand and triglycerides are associated with progression of lower limb arterial calcification in Type 2 Diabetes: a prospective, observational cohort study.

Bourron¹,

Phan²,

Diallo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Lower limb arterial calcification is a frequent, underestimated but serious complication of diabetes. The DIACART study is a prospective cohort study designed to evaluate the determinants of the progression of lower limb arterial calcification in 198 patients with type 2 diabetes. Methods: Lower limb arterial calcification scores were determined by computed tomography at baseline and after a mean follow up of 31.20 +/-3.86 months. Serum RANKL (Receptor Activator of Nuclear factor kB Ligand) and bone remodeling, inflammatory and metabolic parameters were measured at baseline. The predictive effect of these markers on calcification progression was analyzed by a multivariate linear regression model. Results: At baseline, mean+/-SD and median lower limb arterial calcification scores were, 2364+/- 5613 and 527 respectively and at the end of the study, 3739 +/- 6886 and 1355 respectively. Using multivariate analysis, the progression of lower limb arterial log calcification score was found to be associated with (β coefficient [slope], 95%CI, p-value) baseline log(calcification score) (1.02, 1.00–1.04, p<0.001), triglycerides (0.11, 0.03–0.20, p=0.007), log(RANKL) (0.07, 0.02–0.11, p=0.016), previous ischemic cardiomyopathy (0.36, 0.15–0.57, p=0.001), statin use (0.39, 0.06–0.72, p=0.023) and duration of follow up (0.04, 0.01–0.06, p=0.004). Conclusion: In patients with Type 2 Diabetes, lower limb arterial calcification is frequent and can progress rapidly. Circulating RANKL and triglycerides are independently associated with this progression. These results open new therapeutic perspectives in peripheral diabetic calcifying arteriopathy.Trial registration: NCT02431234

show abstract

Section: Discussioncontrasting

confidence: 73%

Circulating Receptor Activator of Nuclear factor kB Ligand and triglycerides are associated with progression of lower limb arterial calcification in Type 2 Diabetes: a prospective, observational cohort study.

Bourron¹,

Phan²,

Diallo

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Recently low levels of Omentin-1, which is an adipokine with anti-inflammatory properties, were shown to be associated with the presence and severity of PAOD in T2D [36]. However inflammatory markers like IL-6 and hsCRP were not associated with the progression of the calcification in our study.…”

Section: Inflammation and Lower Limb Arterial Calcificationcontrasting

confidence: 78%

Circulating Receptor Activator of Nuclear Factor kB Ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study

Bourron

Phan

Diallo

et al. 2020

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background Lower limb arterial calcification is a frequent, underestimated but serious complication of diabetes. The DIACART study is a prospective cohort study designed to evaluate the determinants of the progression of lower limb arterial calcification in 198 patients with type 2 diabetes. Methods Lower limb arterial calcification scores were determined by computed tomography at baseline and after a mean follow up of 31.20 ± 3.86 months. Serum RANKL (Receptor Activator of Nuclear factor kB Ligand) and bone remodeling, inflammatory and metabolic parameters were measured at baseline. The predictive effect of these markers on calcification progression was analyzed by a multivariate linear regression model. Results At baseline, mean ± SD and median lower limb arterial calcification scores were, 2364 ± 5613 and 527 respectively and at the end of the study, 3739 ± 6886 and 1355 respectively. Using multivariate analysis, the progression of lower limb arterial log calcification score was found to be associated with (β coefficient [slope], 95% CI, p-value) baseline log(calcification score) (1.02, 1.00–1.04, p < 0.001), triglycerides (0.11, 0.03–0.20, p = 0.007), log(RANKL) (0.07, 0.02–0.11, p = 0.016), previous ischemic cardiomyopathy (0.36, 0.15–0.57, p = 0.001), statin use (0.39, 0.06–0.72, p = 0.023) and duration of follow up (0.04, 0.01–0.06, p = 0.004). Conclusion In patients with type 2 diabetes, lower limb arterial calcification is frequent and can progress rapidly. Circulating RANKL and triglycerides are independently associated with this progression. These results open new therapeutic perspectives in peripheral diabetic calcifying arteriopathy. Trial registration NCT02431234

show abstract

“…At a cardiovascular level, reduced circulating omentin levels are associated with poor cardiac outcome in patients with heart failure and with the presence of hypertrophic and dilated cardiomyopathy, and they are considered an independent risk factor for the development of peripheral arterial disease and AMI [ 291 , 292 , 293 , 294 , 295 , 296 , 297 ]. Particularly in AMI patients, serum omentin levels significantly increase after 6 months of follow-up, being inversely correlated with CRP and IL-18, suggesting that the increase of omentin could mediate the reduction of inflammation 6 months after the AMI [ 298 ].…”

Section: Role Of Some Adipokines In Inflammatory Processes Associamentioning

confidence: 99%

Adipokines and Inflammation: Focus on Cardiovascular Diseases

Feijóo‐Bandín

Aragón-Herrera

Moraña-Fernández

et al. 2020

IJMS

View full text Add to dashboard Cite

It is well established that adipose tissue, apart from its energy storage function, acts as an endocrine organ that produces and secretes a number of bioactive substances, including hormones commonly known as adipokines. Obesity is a major risk factor for the development of cardiovascular diseases, mainly due to a low grade of inflammation and the excessive fat accumulation produced in this state. The adipose tissue dysfunction in obesity leads to an aberrant release of adipokines, some of them with direct cardiovascular and inflammatory regulatory functions. Inflammation is a common link between obesity and cardiovascular diseases, so this review will summarise the role of the main adipokines implicated in the regulation of the inflammatory processes occurring under the scenario of cardiovascular diseases.

show abstract

Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease

Cited by 54 publications

References 36 publications

Circulating Receptor Activator of Nuclear factor kB Ligand and triglycerides are associated with progression of lower limb arterial calcification in Type 2 Diabetes: a prospective, observational cohort study.

Circulating Receptor Activator of Nuclear factor kB Ligand and triglycerides are associated with progression of lower limb arterial calcification in Type 2 Diabetes: a prospective, observational cohort study.

Circulating Receptor Activator of Nuclear Factor kB Ligand and triglycerides are associated with progression of lower limb arterial calcification in type 2 diabetes: a prospective, observational cohort study

Adipokines and Inflammation: Focus on Cardiovascular Diseases

Contact Info

Product

Resources

About